The U.S. Food and Drug Administration has granted approval to Pfizer and Arvinas for their oral breast cancer medication Veppanu, authorizing its use in adults with estrogen receptor-positive, HER2-negative tumors that have spread or cannot be surgically removed, provided the cancers carry an ESR1 mutation and have shown progression after at least one prior hormone therapy.
The regulator's approval is anchored on results from a late-stage study involving 624 participants. That trial demonstrated that patients receiving Veppanu experienced longer periods without disease progression compared with those treated with the older injectable hormone therapy fulvestrant. The FDA noted that tumors in patients taking the pill shrank more frequently than in those given the injectable comparator.
Arvinas Chief Executive Randy Teel described the approval as delivering an important new option for patients with stage-4 disease. "Patients really are in need of a new modality, a new technology and a new way of hitting disease," he said. Teel also indicated the company expects to announce a commercialization agreement for Veppanu in the coming weeks, after which there should be greater clarity on pricing.
Independent commentary cited in regulatory materials indicated Veppanu's efficacy appears competitive with other approved treatments, though direct comparisons across differing clinical trials complicate definitive differentiation. Wedbush analyst Robert Driscoll said the drug's tolerability profile looked "compelling."
The FDA's label includes safety cautions. The regulator warned the medication can affect heart rhythm and could harm an unborn baby. Recommended dosing is a 200 mg tablet taken once daily with food, continued until the disease worsens or side effects prohibit ongoing treatment.
In addition to the drug approval, the FDA cleared a companion blood-based diagnostic, Guardant360 CDx, to identify patients carrying the ESR1 mutation who would be eligible for treatment with Veppanu.
The approval package leaves certain commercial questions unresolved. While the clinical data provided a basis for authorization and safety information limits use in specific patient groups, the final commercial structure and pricing will depend on forthcoming agreements between the developers and potential partners or distributors.
Key clinical facts:
- Indication: Adults with estrogen receptor-positive, HER2-negative advanced or inoperable breast cancer with ESR1 mutation after progression on at least one hormone therapy.
- Clinical evidence: Late-stage trial of 624 participants showing longer progression-free intervals versus fulvestrant and higher tumor shrinkage rates in pill recipients.
- Dosing and safety: 200 mg once daily with food; risks include effects on heart rhythm and potential harm to an unborn baby.
- Companion diagnostic: Guardant360 CDx blood test approved to identify eligible patients.